C Leland Rogers1, Arie Perry1, Stephanie Pugh1, Michael A Vogelbaum1, David Brachman1, William McMillan1, Joseph Jenrette1, Igor Barani1, Dennis Shrieve1, Andy Sloan1, Joseph Bovi1, Young Kwok1, Stuart H Burri1, Samuel T Chao1, Aaron C Spalding1, Mitchell S Anscher1, Beatrice Bloom1, Minesh Mehta1. 1. Virginia Commonwealth University, Richmond, Virginia (C.L.R., M.S.A.); University of California, San Francisco, California (A.P., I.B.); NRG Oncology Statistics and Data Management Center, Philadelphia, Pennsylvnia (S.P.); Cleveland Clinic Foundation, Cleveland, Ohio (M.A.V., S.T.C.); Arizona Oncology Services Foundation, Phoenix, Arizona (D.B.); McMaster University, Hamilton, Ontario, Canada (W.M.); Medical University of South Carolina, Charleston, South Carolina (J.J.); University of Utah Health Science Center, Salt Lake City, Utah (D.S.); University Hospitals, Cleveland, Ohio (A.S.); Medical College of Wisconsin, Milwaukee, Wisconsin (J.B.); University of Maryland Medical System, Baltimore, Maryland (Y.K., M.M.); Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina (S.H.B.); Norton Cancer Institute, Louisville, Kentucky (A.C.S.); North Shore University Hospital CCOP, Manhasset, New York (B.B.).
Abstract
BACKGROUND: With advances in the understanding of histopathology on outcome, accurate meningioma grading becomes critical and drives treatment selection. The 2000 and 2007 WHO schema greatly increased the proportion of grade II meningiomas. Although associations with progression-free survival (PFS) and overall survival (OS) have been independently validated, interobserver concordance has not been formally assessed. METHODS: Once mature, NRG Oncology RTOG-0539 will report PFS and OS in variably treated low-, intermediate-, and high-risk cohorts. We address concordance of histopathologic assessment between enrolling institutions and central review, performed by a single pathologist (AP), who is also involved in developing current WHO criteria. RESULTS: The trial included 170 evaluable patients, 2 of whom had 2 eligible pathology reviews from different surgeries, resulting in 172 cases for analysis. Upon central review, 76 cases were categorized as WHO grade I, 71 as grade II, and 25 as grade III. Concordance for tumor grade was 87.2%. Among patients with WHO grades I, II, and III meningioma, respective concordance rates were 93.0%, 87.8%, and 93.6% (P values < .0001). Moderate to substantial agreement was encountered for individual grading criteria and were highest for brain invasion, ≥20 mitoses/10 high-powered field [HPF], and spontaneous necrosis, and lowest for small cells, sheeting, and ≥4 mitoses/10 HPF. In comparison, published concordance for gliomas in clinical trials have ranged from 8%-74%. CONCLUSION: Our data suggest that current meningioma classification and grading are at least as objective and reproducible as for gliomas. Nevertheless, reproducibility remains suboptimal. Further improvements may be anticipated with education and clarification of subjective criteria, although development of biomarkers may be the most promising strategy.
BACKGROUND: With advances in the understanding of histopathology on outcome, accurate meningioma grading becomes critical and drives treatment selection. The 2000 and 2007 WHO schema greatly increased the proportion of grade II meningiomas. Although associations with progression-free survival (PFS) and overall survival (OS) have been independently validated, interobserver concordance has not been formally assessed. METHODS: Once mature, NRG Oncology RTOG-0539 will report PFS and OS in variably treated low-, intermediate-, and high-risk cohorts. We address concordance of histopathologic assessment between enrolling institutions and central review, performed by a single pathologist (AP), who is also involved in developing current WHO criteria. RESULTS: The trial included 170 evaluable patients, 2 of whom had 2 eligible pathology reviews from different surgeries, resulting in 172 cases for analysis. Upon central review, 76 cases were categorized as WHO grade I, 71 as grade II, and 25 as grade III. Concordance for tumor grade was 87.2%. Among patients with WHO grades I, II, and III meningioma, respective concordance rates were 93.0%, 87.8%, and 93.6% (P values < .0001). Moderate to substantial agreement was encountered for individual grading criteria and were highest for brain invasion, ≥20 mitoses/10 high-powered field [HPF], and spontaneous necrosis, and lowest for small cells, sheeting, and ≥4 mitoses/10 HPF. In comparison, published concordance for gliomas in clinical trials have ranged from 8%-74%. CONCLUSION: Our data suggest that current meningioma classification and grading are at least as objective and reproducible as for gliomas. Nevertheless, reproducibility remains suboptimal. Further improvements may be anticipated with education and clarification of subjective criteria, although development of biomarkers may be the most promising strategy.
Authors: C B Scott; J S Nelson; N C Farnan; W J Curran; K J Murray; A J Fischbach; L E Gaspar; D F Nelson Journal: Cancer Date: 1995-07-15 Impact factor: 6.860
Authors: R A Prayson; D P Agamanolis; M L Cohen; M L Estes; B K Kleinschmidt-DeMasters; F Abdul-Karim; S P McClure; B A Sebek; R Vinay Journal: J Neurol Sci Date: 2000-04-01 Impact factor: 3.181
Authors: Rebecca A Packer; John H Rossmeisl; Michael S Kent; John F Griffin; Christina Mazcko; Amy K LeBlanc Journal: Vet Radiol Ultrasound Date: 2018-03-09 Impact factor: 1.363
Authors: Martha Nowosielski; Norbert Galldiks; Sarah Iglseder; Philipp Kickingereder; Andreas von Deimling; Martin Bendszus; Wolfgang Wick; Felix Sahm Journal: Neuro Oncol Date: 2017-11-29 Impact factor: 12.300
Authors: Suresh K Balasubramanian; Mayur Sharma; Danilo Silva; Vidhya Karivedu; Philipp Schmitt; Glen H Stevens; Gene H Barnett; Richard A Prayson; Paul Elson; John H Suh; Erin S Murphy; Samuel T Chao Journal: J Neurooncol Date: 2016-11-18 Impact factor: 4.130
Authors: Ganesh M Shankar; Malak Abedalthagafi; Rachael A Vaubel; Parker H Merrill; Naema Nayyar; Corey M Gill; Ryan Brewster; Wenya Linda Bi; Pankaj K Agarwalla; Aaron R Thorner; David A Reardon; Ossama Al-Mefty; Patrick Y Wen; Brian M Alexander; Paul van Hummelen; Tracy T Batchelor; Keith L Ligon; Azra H Ligon; Matthew Meyerson; Ian F Dunn; Rameen Beroukhim; David N Louis; Arie Perry; Scott L Carter; Caterina Giannini; William T Curry; Daniel P Cahill; Frederick G Barker; Priscilla K Brastianos; Sandro Santagata Journal: Neuro Oncol Date: 2017-04-01 Impact factor: 12.300
Authors: C Leland Rogers; Minhee Won; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; Shannon E Fogh; Emad Youssef; Nimisha Deb; Young Kwok; Clifford G Robinson; Hui-Kuo Shu; Barbara J Fisher; Valerie Panet-Raymond; William G McMillan; John F de Groot; Peixin Zhang; Minesh P Mehta Journal: Int J Radiat Oncol Biol Phys Date: 2019-11-29 Impact factor: 7.038
Authors: Leland Rogers; Peixin Zhang; Michael A Vogelbaum; Arie Perry; Lynn S Ashby; Jignesh M Modi; Anthony M Alleman; James Galvin; David Brachman; Joseph M Jenrette; John De Groot; Joseph A Bovi; Maria Werner-Wasik; Jonathan P S Knisely; Minesh P Mehta Journal: J Neurosurg Date: 2017-10-06 Impact factor: 5.115